Pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis

Pharmacology

Volumn 68, Issue 4, 2003, Pages 169-176

  Terata, Yutaka ^a   Saito, Takashi ^a   Fujiwara, Yoshimasa ^a   Hasegawa, Hitoshi ^a   Miura, Hiroto ^b   Watanabe, Hiroyuki ^a   Chiba, Yoshikatsu ^a   Kibira, Satoshi ^a   Miura, Mamoru ^a  

^a AKITA UNIVERSITY   (Japan)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Angiotensin II; AP1; Calcium activated potassium channels; LNAME; NF B; Nitric oxide; Pitavastatin; Statin(s); Vascular remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N(G) NITROARGININE METHYL ESTER; OXIDOREDUCTASE INHIBITOR; PITAVASTATIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORONARY ARTERY; FIBROMUSCULAR DYSPLASIA; HEART MUSCLE ISCHEMIA; HYPERTENSION; HYPOCHOLESTEROLEMIA; IN SITU HYBRIDIZATION; INHIBITION KINETICS; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPHYGMOMANOMETER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ANIMALS; ARTERIOLES; BLOOD PRESSURE; CORONARY VESSELS; FIBROSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN SITU HYBRIDIZATION; LIPIDS; MALE; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; QUINOLINES; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 0038640871     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070455     Document Type: Article

References (33)

1. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
2. Kaiser L, Spickard RC, Oliver NB: Heart failure depresses endothelium-dependent responses in canine femoral artery. Am J Physiol 1989;256:H962-H967.
3. Ku DD: Coronary vascular reactivity after acute myocardial ischemia. Science 1982;218:576-578.
4. Saito T, Fushimi E, Abe T, Kimura Y, Takahashi K, Kudo Y, Nakagomi A, Miura M: Augmented contractile response to endothelin and blunted endothelium-dependent relaxation in post-ischemic reperfused coronary arteries. Jpn Circ J 1992;56:657-670.
5. Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T, Takata Y, Fujishima M: Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ Res 1992;70:660-669.
6. Urakami-Harasawa M, Shimokawa H, Nakashima M, Egashira K, Takeshita A: Importance of endothelium-derived hyperpolarizing factor in humans. J Clin Invest 1997;100:2793-2799.
7. Najibi S, Cowan CL, Palacio JJ, Cohen RA: Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol 1994;266:H2061-H2067.
8. McCulloch AI, Bottrill FE, Randall MD, Hiley R: Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. B. J Pharmacol 1997;120:1431-1438.
9. + current is enhanced in arterial membranes of hypertensive rats. Hypertension 1992;19:301-307.
10. + channels in aorta of hypertensive rats. Hypertension 1997;30:1403-1409.
11. + channels in postichaemic heart. Clin Exp Pharmacol Physiol2002;29:324-329.
12. ca channel diversity and smooth muscle cell function. Circ Res 1999;85:e33-e43.
13. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, Chandy KG: Up-regulation of the IKCa1 potassium channel during T-cell activation: Molecular mechanism and functional consequences. J Biol Chem 2000;275:37137-37149.
14. Ca channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-β suppression of myogenesis. J Biol Chem 2000;275:13677-13682.
15. Laufs U, Fata VL, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
16. Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R: Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991;23:173-180.
17. Hidaka Y, Eda T, Yonemoto M, Kamei T: Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992;95:87-94.
18. Pruefer D, Scalia R, Lefer AN: Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Res 1999;19:2894-2900.
19. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A: Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutanyl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:1896-1901.
20. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A: Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995;26:957-962.
21. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A: Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;99:278-287.
22. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A: Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998;83:743-751.
23. Kurose I, Wolf R, Grisham MB, Aw TY, Specian RD, Granger DN: Microvascular responses to inhibition of nitric oxide production: Role of active oxidants. Circ Res 1995;76:30-39.
24. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
25. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS: Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990;10:5536-5540.
26. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y: Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittel-Forsch 1997;47:904-909.
27. Kajinami K, Mabuchi H, Saito Y: NK-104: A novel synthetic HMG-CoA reductase inhibitor. Expert Opin Invest Drugs 2000;9:2653-2661.
28. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974.
29. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 2001;104:576-581.
30. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, Takeshita A: Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001;89:415-421.
31. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000;58:1420-1430.
32. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001;107:1423-1432.
33. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002;290:131-139.